Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
$1.61
+0.4%
$1.71
$0.99
$8.77
$82.71M2.71.67 million shs930,473 shs
Climb Bio, Inc. stock logo
CLYM
Climb Bio
$1.28
+1.6%
$1.24
$1.05
$9.21
$86.50M-0.13408,667 shs158,764 shs
Generation Bio Co. stock logo
GBIO
Generation Bio
$0.35
+3.0%
$0.38
$0.30
$3.65
$22.99M2.59395,068 shs676,584 shs
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$11.36
+4.6%
$8.27
$6.53
$30.60
$103.65M2.75134,471 shs107,170 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
0.00%+2.29%-26.33%+44.68%-78.73%
Climb Bio, Inc. stock logo
CLYM
Climb Bio
0.00%+8.47%+3.23%+9.40%+127,999,900.00%
Generation Bio Co. stock logo
GBIO
Generation Bio
0.00%+15.85%-4.81%-6.58%-85.74%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
0.00%+24.78%+56.40%-11.29%-19.10%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
1.5431 of 5 stars
3.52.00.00.00.00.80.6
Climb Bio, Inc. stock logo
CLYM
Climb Bio
2.6433 of 5 stars
3.60.00.00.00.62.51.3
Generation Bio Co. stock logo
GBIO
Generation Bio
2.9633 of 5 stars
3.53.00.00.00.03.31.3
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
3.5634 of 5 stars
2.92.00.04.62.80.80.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
3.00
Buy$14.43798.42% Upside
Climb Bio, Inc. stock logo
CLYM
Climb Bio
3.25
Buy$9.00603.13% Upside
Generation Bio Co. stock logo
GBIO
Generation Bio
3.00
Buy$7.332,007.28% Upside
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
1.75
Reduce$73.67548.76% Upside

Current Analyst Ratings Breakdown

Latest GBIO, CLYM, CABA, and MCRB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/11/2025
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
6/6/2025
Climb Bio, Inc. stock logo
CLYM
Climb Bio
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$10.00
5/22/2025
Climb Bio, Inc. stock logo
CLYM
Climb Bio
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
5/22/2025
Climb Bio, Inc. stock logo
CLYM
Climb Bio
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$7.00
5/16/2025
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$17.00 ➝ $13.00
5/15/2025
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$23.00 ➝ $25.00
5/8/2025
Generation Bio Co. stock logo
GBIO
Generation Bio
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
5/8/2025
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$1.25 ➝ $6.00
4/10/2025
Generation Bio Co. stock logo
GBIO
Generation Bio
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
N/AN/AN/AN/A$3.12 per shareN/A
Climb Bio, Inc. stock logo
CLYM
Climb Bio
N/AN/AN/AN/A$3.15 per shareN/A
Generation Bio Co. stock logo
GBIO
Generation Bio
$19.89M1.17N/AN/A$1.29 per share0.27
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$126.32M0.78N/AN/A$1.61 per share7.05
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
-$115.86M-$2.54N/AN/AN/AN/A-78.29%-65.68%8/6/2025 (Estimated)
Climb Bio, Inc. stock logo
CLYM
Climb Bio
-$73.90M-$2.38N/AN/AN/AN/A-43.95%-42.94%8/13/2025 (Estimated)
Generation Bio Co. stock logo
GBIO
Generation Bio
-$131.67M-$1.08N/AN/AN/A-292.92%-75.84%-30.40%8/6/2025 (Estimated)
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$140K-$4.60N/AN/AN/AN/A-41,084.76%-55.87%8/12/2025 (Estimated)

Latest GBIO, CLYM, CABA, and MCRB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/21/2025Q1 2025
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
-$0.67-$0.71-$0.04-$0.71N/AN/A
5/14/2025Q1 2025
Climb Bio, Inc. stock logo
CLYM
Climb Bio
-$0.15-$0.31-$0.16-$0.31N/AN/A
5/7/2025Q1 2025
Generation Bio Co. stock logo
GBIO
Generation Bio
-$0.25-$0.22+$0.03-$0.22$1.70 million$8.72 million
5/7/2025Q1 2025
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
-$0.67-$2.24-$1.57$3.75$10.00 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
N/AN/AN/AN/AN/A
Climb Bio, Inc. stock logo
CLYM
Climb Bio
N/AN/AN/AN/AN/A
Generation Bio Co. stock logo
GBIO
Generation Bio
N/AN/AN/AN/AN/A
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
N/A
3.96
3.96
Climb Bio, Inc. stock logo
CLYM
Climb Bio
N/A
14.25
14.25
Generation Bio Co. stock logo
GBIO
Generation Bio
N/A
8.43
8.43
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
N/A
2.11
2.11

Institutional Ownership

CompanyInstitutional Ownership
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
N/A
Climb Bio, Inc. stock logo
CLYM
Climb Bio
69.76%
Generation Bio Co. stock logo
GBIO
Generation Bio
95.22%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
59.34%

Insider Ownership

CompanyInsider Ownership
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
11.25%
Climb Bio, Inc. stock logo
CLYM
Climb Bio
0.80%
Generation Bio Co. stock logo
GBIO
Generation Bio
21.80%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
4.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
5050.74 million45.03 millionOptionable
Climb Bio, Inc. stock logo
CLYM
Climb Bio
967.58 million67.04 millionN/A
Generation Bio Co. stock logo
GBIO
Generation Bio
15067.04 million52.42 millionOptionable
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
3308.73 million8.32 millionOptionable

Recent News About These Companies

Seres Therapeutics trading resumes
Seres Therapeutics trading halted, volatility trading pause
Seres Therapeutics trading halted, news pending

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cabaletta Bio stock logo

Cabaletta Bio NASDAQ:CABA

$1.61 +0.01 (+0.38%)
Closing price 07/3/2025 03:47 PM Eastern
Extended Trading
$1.64 +0.04 (+2.43%)
As of 07/3/2025 04:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Climb Bio stock logo

Climb Bio NASDAQ:CLYM

$1.28 +0.02 (+1.59%)
As of 07/3/2025 01:00 PM Eastern

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Generation Bio stock logo

Generation Bio NASDAQ:GBIO

$0.35 +0.01 (+2.99%)
Closing price 07/3/2025 03:42 PM Eastern
Extended Trading
$0.35 0.00 (0.00%)
As of 07/3/2025 04:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Seres Therapeutics stock logo

Seres Therapeutics NASDAQ:MCRB

$11.36 +0.50 (+4.56%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$11.94 +0.58 (+5.11%)
As of 07/3/2025 04:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.